Market leader GW Pharmaceuticals (GWPH) started to come back from a sell-off period in late December. Anticipator buying prior to GW’s Sativex results saw the stock rise from $67 to highs of $80.68. Unfortunately for the company and the stock as of recent weeks, results were dismal.
Oxis International, Inc. operates through its subsidiary Oxis Biotech, Inc. The company has recently come into the cannabis biotech space and may represent the greatest potential reward of all the companies on this list considering where the company’s valuation stands today, an approximate market cap of just $15million.
To read more, visit http://finance.yahoo.com/news/top-5-cannabis-stocks-watch-143600925.html
In January 2015 it got a fresh hit from an announcement that Silicon Valley-based Founders Fund, led by PayPal co-founder Peter Thiel, is participating in a $75 million funding round to help Privateer expand.
The hype has been building since cover stories in Fortune and USA Today on Privateer Holdings, the nation’s first private equity fund for marijuana, ran within days of each other in 2013.
American Green(ERBB). CannaGrow Holdings (CGRW). Hemp (HEMP). Medical Marijuana (MJNA). WeedHire International (WDHR). (Amusingly, the stock with the ticker symbol is THC is not a pot firm but giant hospital owner Tenet (THC).)
These companies are basically wrapping themselves in a red, yellow and green flag with a leaf and the date 4/20 on it.
To read more, visit http://money.cnn.com/2015/04/17/investing/marijuana-stocks-pot-gw-pharmaceuticals/
Insys Therapeutics Inc has also focused on cannabinoid therapy. They develop novel drugs and delivery methods using methods such as sublingual sprays. The company’s two main products include Subsys(R), a sublingual Fentanyl spray to help with cancer pain and a generic version of Dronabinol capsules or THC capsules.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) reported earlier this month that it has begun to undertake the second of two Phase 3 trials of their Epidiolex(R), administered for therapies concerning Lennox-Gastaut syndrome. This is a unique and debilitating form of “childhood-onset epilepsy.”
To read more, visit http://www.wfla.com/story/29345131/these-cannabis-stocks-are-smoking-hot-right-now
Marijuana has been hailed as an effective treatment for pain, cancer, epilepsy, glaucoma, and more. New reports show marijuana is also effective in treating Alzheimer’s disease.
Research published September 2014 in the Journal of Alzheimer’s Disease “strongly suggests that THC (the main active ingredient in marijuana) could be a potential therapeutic treatment option for Alzheimer’s disease through multiple functions and pathways.”
As what people can see, the medicinal uses for marijuana is adding up and that is why some people have seen a bright lucrative future ahead of them is they invest in marijuana stocks.
To read more, visit http://moneymorning.com/2015/06/17/are-there-good-marijuana-stocks-to-invest-in-now/